- $500.80bn
- $565.10bn
- $61.16bn
U.S. STOCKS ON THE MOVE-Apple, Reddit, Roblox
AbbVie falls after trimming 2026 profit forecast
AbbVie beats Q2 revenue, adjusted EPS estimates but cuts FY adj EPS guidance
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
Corrected: BRIEF-AbbVie Inc outlook FY adjusted EPS USD 13.87 - 14.07
Morning Bid Europe: Yen sinks as BOJ holds - and it's the KOSPI's best day
Sarepta names former Abbvie president as CEO as Ingram retires
Brief: Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Regenxbio tumbles on deep-discounted $100 mln equity offering
Regenxbio slides after unveiling $100 mln stock offering
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal (updated)
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology
BMO lifts AbbVie PT, sees continued strength in immunology drugs
U.S. STOCKS ON THE MOVE-Circle Internet, Solaris Energy, Fermi
U.S. STOCKS ON THE MOVE-Circle Internet, Solaris Energy, Fermi